About 3DHEALS Company Directory:

3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members. 

THIS CONTENT IS FOR PREMIUM AND ENTERPRISE MEMBERS ONLY.

Register

Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

Organization Name
Categories
Headquater location
Description

Lung Biotechnology PBC

At Lung Biotechnology we believe serving others is more than just a responsibility – it’s a privilege.

Headquarters 1040 Spring Street Silver Spring MD 20910 United States
Categories: Bioprinting /Biofabrication, Tissue Engineering
Website: omg.unither.com/
CEO: Martine Rothblatt, PhD, JD President and CEO Phone: 1-800-545-5979
Links:

Details

United Therapeutics Corporation was founded in 1996 by Martine Rothblatt after her daughter was diagnosed with pulmonary arterial hypertension (PAH). A biotech company born out of exceptional circumstances, United Therapeutics develops unique products for chronic and life-threatening cardiovascular diseases as well as cancer.

Lung Biotechnology was established in 2006 (originally called LungRx) as part of United Therapeutics’ work to address the severe shortage of transplantable organs in the U.S. The company focuses on technologies that either delay the need for transplants or expand the supply of donor organs. Its latest partnerships include that with 3D Systems, Collplants, among others. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Founded in 2014, Lung Bioengineering Inc. is a wholly-owned subsidiary of Lung Biotechnology PBC, a patient-facing organization. Its mission is to be the most trusted provider of centralized organ services. It aims to deliver a seamless customer experience and support innovative research to expand the supply of transplantable organs. As of September 2020, 150 lungs that went through EVLP at Lung Bioengineering have been transplanted as part of its clinical trials.* This number reflects our potential impact in the transplant field.

For more timeline-related info, please see the company’s website.